Form 6-K Clinuvel Pharmaceuticals For: Jul 21

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of July 2026

 

Commission File Number: 001-43353

 

CLINUVEL PHARMACEUTICALS LIMITED

 

Level 22, 535 Bourke Street

Melbourne, VIC 3000

Australia

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F ☒ Form 40-F ☐

 

 

 

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

 

On July 21, 2026, Clinuvel Pharmaceuticals Limited filed with the Australian Securities Exchange an announcement captioned “CLINUVEL’s ADS commences trading on Nasdaq”, a copy of which announcement is attached to this Form 6-K as Exhibit 99.1.

 

Exhibits

 

Exhibit No.		Description
99.1		Press release dated July 21, 2026

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	CLINUVEL PHARMACEUTICALS LIMITED
Date: July 21, 2026	By:	/s/ Philippe Wolgen
	Name:	Philippe Wolgen
	Title:	Managing Director and Chief Executive Officer

 

ATTACHMENTS / EXHIBITS

EX-99.1

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• CLINUVEL implements strategic reorganisation to refocus on U.S. markets
• New INE Research Finds Just 22% of Organizations Feel Prepared for AI-Driven Cybersecurity Operations
• ORCA Joins Coinfest Asia 2026 in Bali to Showcase Its AI Agent Infrastructure